Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Cost of Revenue (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Cost of Revenue for 16 consecutive years, with $78041.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 95.18% year-over-year to $78041.0, compared with a TTM value of -$4.4 million through Sep 2025, down 178.73%, and an annual FY2024 reading of $528824.0, down 92.75% over the prior year.
  • Cost of Revenue was $78041.0 for Q3 2025 at China Pharma Holdings, up from -$1.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.3 million in Q4 2021 and bottomed at -$4.7 million in Q4 2024.
  • Average Cost of Revenue over 5 years is $1.3 million, with a median of $445478.0 recorded in 2021.
  • The sharpest move saw Cost of Revenue skyrocketed 1542.06% in 2021, then tumbled 1072.54% in 2025.
  • Year by year, Cost of Revenue stood at $8.3 million in 2021, then dropped by 5.3% to $7.9 million in 2022, then crashed by 71.76% to $2.2 million in 2023, then tumbled by 310.48% to -$4.7 million in 2024, then skyrocketed by 101.66% to $78041.0 in 2025.
  • Business Quant data shows Cost of Revenue for CPHI at $78041.0 in Q3 2025, -$1.1 million in Q2 2025, and $1.3 million in Q1 2025.